Kanitinib in Treating Patients With Advanced Solid Tumors

NCT02916095 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Kanitinib

Sponsor

Beijing Konruns Pharmaceutical Co., Ltd.

Collaborators

[object Object]